Riskpilot← Back to searchSign inGet full accessBiotech-IgG Securities (publ) AB
ABBankruptOrg 5590179437Research and experimental development on natural sciences and engineering · NACE 7210Est. 20150 employees
Revenue 2022
SEK 0
EBITDA margin
—
-63% vs 2021
Equity ratio
4.7%
Financial strength
Net profit 2022
SEK -204K
+44% vs 2021
| Revenue | SEK 0 | — |
| EBITDA | SEK -204K | -63% |
| Net profit | SEK -204K | +44% |
| Total assets | SEK 10,7M | +3% |
| Equity | SEK 506K | +63% |
| Employees | 0 | — |
Legal name
Biotech-IgG Securities (publ) AB
Org number
5590179437
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
22 juni 2015
Share capital
SEK 615 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2022-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna Registrerad kvalificerad revisor saknas.
Company purpose
Bolaget ska bedriva verksamhet form av forskning, handel och tillverkning inom områdena sensorteknologi och instrumentteknik. Bolaget ska även bedriva förvaltnings- verksamhet genom att direkt eller indirekt förvärva, förvalta, förmedla och avyttra aktier, andelar samt övriga finansiella tillgångar i syfte att skapa värdetillväxt för bolagets ägare. Bolagets ska även kunna bedriva med ovanstående verksamheter förenlig verksamhet.
Address
Email
glenn@renhult.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 1 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −151 | −115 | −96 | −125 | −204 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −151 | −115 | −96 | −125 | −204 |
| Net financials | −89 919 | −765 | −632 | −238 | — |
| Profit before tax | −90 070 | −574 | −728 | −363 | −204 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −90 070 | −574 | −728 | −363 | −204 |
| Item | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Total assets | 477 | 11 445 | 10 815 | 10 350 | 10 661 |
| Equity | 326 | 951 | 223 | 310 | 506 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 151 | 10 493 | 10 592 | 10 040 | 10 155 |
| Total debt | 151 | 10 493 | 10 592 | 10 040 | 10 155 |
EBITDA margin
-20400000.0%
This company
15.8%
Market median
-129114024% vs market
20182022
Equity ratio
4.7%
This company
38.2%
Market median
-88% vs market
20182022
Return on equity
-40.3%
This company
18.4%
Market median
-319% vs market
20182022
Net profit margin
-20400000.0%
This company
8.1%
Market median
-251851952% vs market
20182022
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20182022
Debt / equity
20.07×
This company
0.62×
Market median
-3137% vs market
20182022
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
HG Chief Executive Officer | Chief Executive Officer | 2021 |
| Former (4) | ||
KE | Audit | 2021 – 2022 |
LG Audit | Audit | 2023 – 2023 |
IT Chief Auditor | Chief Auditor | 2022 – 2024 |
IE Audit | Audit | 2021 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2021 | |
| Chairman | 2021 | |
| Former (2) | ||
| Chairman | 2023 – 2023 | |
| Chairman | 2023 – 2023 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Biotech-IgG Equity AB (publ)
Biotech-IgG Securities (publ) AB Board members of Biotech-IgG Securities (publ) AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Hugo Glenn Renhult | Chief Executive Officer | 0 companies |
| Karl Erik Göran Bringer | Audit | 0 companies |
| Leif Gunnar Skarle | Audit | 0 companies |
| Ivan Ticic | Chief Auditor | 0 companies |
| Isabella Eva Rümmer | Audit | 0 companies |
| Johan Karl-Herbert Lee Backman | Board of Directors | 0 companies |
| Per Wilhelm Wåhlin | Chairman | 0 companies |
| Leif Gustaf Malmborg | Chairman | 0 companies |
| Ingemar Håkan Karlsson | Chairman | 0 companies |